FDA withdrawing proposals
This article was originally published in The Tan Sheet
GMPs for homeopathic products, "Food Labeling, Nutrient Content Claims & Health Claims" among draft proposals FDA is considering withdrawing, according to 1April 22 Federal Register notice. Agency plans to withdraw 84 proposed rules that have not been finalized, are not considered public health priorities, and which have not received agency action in more than 10 years. "FDA's actions are part of an overall regulatory reform strategy initiated by" HHS Secretary Tommy Thompson, the notice states. Commissioner Mark McClellan, MD/PhD, says action is consistent with agency's commitment to "transparency in its regulatory actions." FDA has included a 2press release and 3FAQ page on its Web site to clear up uncertainties; comments will be accepted through July 21...
You may also be interested in...
Hanmi showcases at JPM its contract production capabilities for COVID-19 vaccines as South Korea prepares to bring in candidates from several global developers, while LG Chem highlights progress across multiple pipeline projects.
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.